Chromadex Profit Margin

The latest profit margin for CDXC is Infinity% as of March 2026. That compares with 16.25% in the prior-year period — up Infinity% year over year. That is above the Healthcare sector average of 15.58%. Investors often review this figure alongside Chromadex's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDXC's profit margin moved from 16.25% to Infinity% — a Infinity% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chromadex's valuation or profitability profile.

Against Healthcare companies, CDXC currently prints Infinity% for profit margin, while the sector average sits near 15.58%. That is roughly Infinity% above the sector mean. Large gaps often invite a closer look at Chromadex's growth, margins, and balance sheet.

Profit Margin shows how effectively Chromadex converts resources into returns. At Infinity%, CDXC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 16.25% in the prior-year period — up Infinity% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CDXC's profit margin (Infinity%), review year-over-year change from 16.25%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.